The Lung IDx Program has a primary focus on early lung cancer detection. The program captures patients from the Lung Screening Program, patients under evaluation for incidentally-detected lung nodules, and patients who undergo percutaneous lung biopsy for an indeterminate lung nodule.
Patients enrolled into the database are followed to tissue diagnosis. In patients with lung cancer diagnoses, first line treatments are captured. The program is supported by a number of extramurally funded grants and contracts.
The Lung IDx Program has centered on the characterization of lung nodules to distinguish benign from malignant lesions as well as to better characterize and predict the biological behavior of early lung cancers, with the goals of expediting early diagnosis and informing management strategies designed to reduce mortality and prolong survival in those with the diagnosis of lung cancer.
Lung IDx captures detailed sociodemographic, medical, medical imaging, and digital pathology imaging sources, including detailed risk questionnaires for lung cancer. Beyond histologic and mutational analyses, additional readily accessible biospecimens may be collected in these consented patients, including saliva samples, blood samples for DNA mutations and DNA hypermethylation signatures, and nasal epithelial specimens.